CJC-1295 research

Studies this site relies on

Ordered by strength of design. Conclusions are quoted verbatim from each abstract as indexed by PubMed; read the full paper before relying on any of them.

1. Randomized trial J Clin Endocrinol Metab · 2006 PMID 16352683

   Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults

   Teichman SL, Neale A, Lawrence B, et al.

   Subcutaneous administration of CJC-1295 resulted in sustained, dose-dependent increases in GH and IGF-I levels in healthy adults and was safe and relatively well tolerated, particularly at doses of 30 or 60 microg/kg. There was evidence of a cumulative effect after multiple doses. These data support the potential utility of CJC-1295 as a …

2. Clinical trial J Clin Endocrinol Metab · 2006 PMID 17018654

   Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog

   Ionescu M, Frohman LA

   CJC-1295 increased trough and mean GH secretion and IGF-I production with preserved GH pulsatility. The marked enhancement of trough GH levels by continuous GHRH stimulation implicates the importance of this effect on increasing IGF-I. Long-acting GHRH preparations may have clinical utility in patients with intact pituitary GH secretory …

3. Primary study Growth Horm IGF Res · 2009 PMID 19386527

   Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects

   Sackmann-Sala L, Ding J, Frohman LA, et al.

   Although the molecular mechanisms linking the identified proteins to GH and IGF-1 biological activity remain to be clarified, the results suggest that they represent potential biomarkers of GH and/or IGF-1 action.

Clinical-trial publications in PubMed

2 records carry PubMed’s clinical-trial publication type. Tagging is done by NLM indexers and occasionally includes secondary analyses.

Newest records

The most recent PubMed additions for this query at the data-edition date, regardless of design.

• Detection of CJC-1295 in Equine Plasma by ELISA Drug Test Anal · 2026 · Primary study
• Peptides in urology and sexual medicine: clinical effectiveness, dosing, indications, and safety: a narrative review Sex Med Rev · 2026 · Review
• Peptide Supplements and Their Therapeutic Applications in Sports Medicine Am J Sports Med · 2026 · Primary study
• Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance Sports Med · 2026 · Review
• A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review J Sports Med Phys Fitness · 2026 · Review
• The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration Front Endocrinol (Lausanne) · 2026 · Review
• Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications JBJS Rev · 2026 · Review
• Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives Int J Mol Sci · 2026 · Review
• Therapeutic peptides in gerontology: mechanisms and applications for healthy aging Front Aging · 2026 · Review
• Analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry J Pharm Biomed Anal · 2026 · Primary study